Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

117.93
-0.8800-0.74%
Volume:216.88K
Turnover:25.47M
Market Cap:9.81B
PE:-36.71
High:118.61
Open:116.92
Low:116.28
Close:118.81
52wk High:130.05
52wk Low:39.84
Shares:83.15M
Float Shares:64.87M
Volume Ratio:0.50
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.50
PE(LYR):-31.96

Loading ...

Kymera Therapeutics director Elena Ridloff disposes of 3,000 shares for $261,000

Reuters
·
May 12

Kymera Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
May 07

Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target

MT Newswires Live
·
May 06

Kymera Therapeutics to join Bank of America Healthcare Conference fireside chat

Reuters
·
May 06

Kymera says KT-579 Phase 1 healthy-volunteer trial data due in 2H 2026

Reuters
·
May 05

Jeito Capital appoints Elaine Caughey partner for business development, investor relations

Reuters
·
May 05

Barclays Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

TIPRANKS
·
May 01

Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley

TIPRANKS
·
May 01

Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss

MT Newswires Live
·
Apr 30

Kymera publishes corporate presentation on oral protein degraders for immunology medicines

Reuters
·
Apr 30

Kymera Therapeutics Q1 EPS $(0.71) Beats $(0.88) Estimate, Sales $34.365M Beat $8.614M Estimate

Benzinga Earnings
·
Apr 30

Kymera Q1 revenue jumps on Gilead milestone

Reuters
·
Apr 30

Kymera Q1 net loss widens to $69.2 million; collaboration revenues climb to $34.4 million

Reuters
·
Apr 30

BRIEF-Kymera Therapeutics Q1 EPS USD -0.71

Reuters
·
Apr 30

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

GlobeNewswire
·
Apr 30

Kymera CEO Nello Mainolfi disposes of common shares worth $2,430,898.39

Reuters
·
Apr 30

Kymera director Bruce Booth disposes of common shares worth $538,687

Reuters
·
Apr 25

Kymera COO Jeremy Chadwick disposes 300 shares for $27,000

Reuters
·
Apr 25

Kymera Therapeutics to report first-quarter financial results, host webcast call

Reuters
·
Apr 23

Kymera COO Jeremy Chadwick disposes of USD 589,510 Kymera Therapeutics shares

Reuters
·
Apr 17